AMY RADATZ: Open Payments
NPI 1972145803 · SALINA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 37 payments from 19 companies in 2025. Trend: 2023 $1,353 · 2024 $1,119 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 6 | $195 |
| Novartis Pharmaceuticals Corporation | 4 | $76 |
| Novo Nordisk Inc | 4 | $65 |
| Amgen Inc. | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Travere Therapeutics, Inc. | 3 | $48 |
| ABBVIE INC. | 2 | $34 |
| Eisai Inc. | 1 | $34 |
| GENZYME CORPORATION | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
Products named: TARPEYO, TAVNEOS, LEQVIO, VRAYLAR, Leqembi, Fabhalta, BREZTRI, Rybelsus.
Industry payments across KS — which companies pay providers there.
